Page last updated: 2024-11-05

c.i. direct blue 1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID17461
CHEMBL ID311909
CHEMBL ID1368261
SCHEMBL ID14413257
MeSH IDM0053355

Synonyms (41)

Synonym
CHEMBL311909 ,
chicago sky blue 60
nsc631567
4-amino-6-[(4-{4-[(8-amino-1-hydroxy-5,7-disulfo(2-naphthyl))diazenyl]-3-methoxyphenyl}-2-methoxyphenyl)diazenyl]-5-hydroxynaphthalen-1,3-disulfonic acid
nd-8731
4-amino-6-[(z)-[4-[4-[(z)-(8-amino-1-hydroxy-5,7-disulfo-2-naphthyl)azo]-3-methoxy-phenyl]-2-methoxy-phenyl]azo]-5-hydroxy-naphthalene-1,3-disulfonic acid
NCI60_042146
BPBIO1_000452
BSPBIO_000410
PRESTWICK3_000425
PRESTWICK2_000425
direct blue 1
airedale blue ffd
nsc51538
nd-8792
nsc9617
chicago sky blue 6b
3-amino-5-[(4-{4-[(8-amino-1-hydroxy-5,7-disulfo(2-naphthyl))diazenyl]-3-methoxyphenyl}-2-methoxyphenyl)diazenyl]-4-hydroxynaphthalen-1,2,5,8a-tetrasulfonic acid
pontamine sky blue
c.i. 24410
4-amino-6-[4-[4-[(8-amino-1-hydroxy-5,7-disulfo-2-naphthyl)azo]-3-methoxy-phenyl]-2-methoxy-phenyl]azo-5-hydroxy-naphthalene-1,3-disulfonic acid
nd-10083
PRESTWICK1_000425
PRESTWICK0_000425
SPBIO_002349
bis[4-amino-5-hydroxy-6-(2-methoxy-phenylazo)-naphthalene-1,3-disulfonic acid](chicago sky blue)
bdbm50113317
unii-r1ujk1uy9r
1,3-naphthalenedisulfonic acid, 6,6'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(4-amino-5-hydroxy-
r1ujk1uy9r ,
einecs 223-333-5
3841-14-3
direct blue 1 acid
6,6'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(azo))bis(4-amino-5-hydroxynaphthalene-1,3-disulphonic) acid
BRD-K56483981-342-01-5
c.i. direct blue 1, free acid
DTXSID3063207
CHEMBL1368261
SCHEMBL14413257
BRD-K56483981-342-04-9
Q27287678

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse effects on anterior and posterior segments were evaluated by slit lamp biomicroscopy and ophthalmoscopy."( Administration of novel dyes for intraocular surgery: an in vivo toxicity animal study.
Eibl, K; Freyer, W; Haritoglou, C; Kampik, A; Mankowska, A; May, CA; Rejdak, R; Schuettauf, F; Thaler, S; Zrenner, E, 2006
)
0.33
"BPB or LGSF produced no significantly detectable toxic effects on the retina in vivo."( Administration of novel dyes for intraocular surgery: an in vivo toxicity animal study.
Eibl, K; Freyer, W; Haritoglou, C; Kampik, A; Mankowska, A; May, CA; Rejdak, R; Schuettauf, F; Thaler, S; Zrenner, E, 2006
)
0.33
" Phytotoxicity study revealed the less toxic nature of the metabolites compared to the dye."( Biotransformation of Direct Blue 1 by a moderately halophilic bacterium Marinobacter sp. strain HBRA and toxicity assessment of degraded metabolites.
Arun Prasad, AS; Bhaskara Rao, KV; Satyanarayana, VS, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
"), the dose-response curve of dye leakage against the challenge dose of lipopolysaccharide shifted about 2-fold to the higher dose."( Tolerance to lipopolysaccharide-induced increase in vascular permeability in mouse skin.
Fujii, E; Irie, K; Muraki, T; Ogawa, A; Ohba, K; Tsukahara, F; Uchida, Y, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium/bile acid cotransporterHomo sapiens (human)IC50 (µMol)4.05001.00005.92679.6000AID1896148; AID1896149
Vesicular glutamate transporter 3Rattus norvegicus (Norway rat)Ki0.19000.04000.11500.1900AID216240
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
sodium ion transportSodium/bile acid cotransporterHomo sapiens (human)
response to organic cyclic compoundSodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportSodium/bile acid cotransporterHomo sapiens (human)
response to nutrient levelsSodium/bile acid cotransporterHomo sapiens (human)
bile acid signaling pathwaySodium/bile acid cotransporterHomo sapiens (human)
response to estrogenSodium/bile acid cotransporterHomo sapiens (human)
response to ethanolSodium/bile acid cotransporterHomo sapiens (human)
symbiont entry into host cellSodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportSodium/bile acid cotransporterHomo sapiens (human)
cellular response to xenobiotic stimulusSodium/bile acid cotransporterHomo sapiens (human)
regulation of bile acid secretionSodium/bile acid cotransporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
virus receptor activitySodium/bile acid cotransporterHomo sapiens (human)
protein bindingSodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activitySodium/bile acid cotransporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneSodium/bile acid cotransporterHomo sapiens (human)
basolateral plasma membraneSodium/bile acid cotransporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1896149Inhibition of human NTCP mediated TCA uptake in U2OS expresseing HA-tagged NTCP cells preincubated for 10 mins followed by substrate addition and measured after 2 mins using [3H]-taurocholate as substrate by liquid scintillation counter analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
AID216240Evaluated for competitive inhibition against Vesicular glutamate transporter (VGLUT), and Ki value was reported.2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport.
AID1896148Inhibition of preS1-peptide binding to human HA-tagged NTCP in U2OS expresseing NTCP in incubated for 24 hrs using Myrcludex B as substrate by competitive binding assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
AID1126820Inhibition of rat brain VGLUT assessed as inhibition of [3H]glutamate uptake into vesicles after 10 mins by scintillation spectrophotometry2014European journal of medicinal chemistry, May-06, Volume: 78Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (84)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (11.90)18.7374
1990's16 (19.05)18.2507
2000's25 (29.76)29.6817
2010's26 (30.95)24.3611
2020's7 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.20 (24.57)
Research Supply Index4.55 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.08%)5.53%
Reviews1 (1.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other91 (97.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]